News & Updates

Use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) may reduce the risk of new-onset atrial fibrillation (AF) relative to glucagon-like peptide-1 receptor agonists (GLP-1RAs) in Asian patients with type 2 diabetes mellitus (T2DM) in a real-world practice, reports a recent study.

In Japan, the declaration of a state of emergency in response to the COVID-19 pandemic led to negative metabolic consequences in people with glucose intolerance, such as lowered skeletal muscle and increased body weight and body fat, a recent study has found.

In patients with of type 2 diabetes (T2D), glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) deliver similar improvements in glycaemic control, without increasing weight and hypoglycaemic events over 6 months of treatment, according to data from the retrospective RESTORE-2 NAIVE study.

A post hoc analysis of the SUSTAIN 6 and PIONEER 6 trials has found that semaglutide reduces incidence of any stroke in people with type 2 diabetes (T2D) at high cardiovascular (CV) risk vs placebo.

Serum concentrations of fibroblast growth factor-21 (FGF-21) are elevated in women with gestational diabetes mellitus (GDM), a recent study has found.

Hypertensive patients who work shifts face an increased risk of developing more than two cardiometabolic diseases or cardiometabolic multimorbidity, according to a study.

Patients with diabetes mellitus (DM) who also have atrial fibrillation (AF) are at a heightened risk of developing end-stage renal disease (ESRD), a recent study has found.